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Abstract Prion-related diseases are accompanied by neurode-
generation, astroglial proliferation and formation of proteinase
K-resistant aggregates of the scrapie isoform of the prion protein
(PrPSc). The synthetic PrP fragment 106-126 was reported to be
neurotoxic towards cultured rat hippocampal neurons (Forloni,
G., Angeretti, N., Chiesa, R., Monzani, E., Salmona, M.,
Bugiani, O. and Tagliavini, F. (1993) Nature 362, 543^546) and
mouse cortical cells (Brown, D.R., Herms, J. and Kretzschmar,
H.A. (1994) Neuroreport 5, 2057^2060). However, we found the
viability of these and other neuronal cell types not to be impaired
in the presence of PrP106-126 under widely varied sets of
conditions. Aged preparations of the peptide as well as synthetic
deamidated and isomerized derivatives that correspond to the
aging products of the peptide proved also to lack neurotoxicity.
Apparently, PrP106-126 cannot serve as a model for the
interaction of PrP with neuronal cells.
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1. Introduction
The cellular prion protein (PrPc) is a glycoprotein of un-
known function found at the surface mainly of neurons [1]
and glial cells [2]. The normal PrP is converted by an un-
known mechanism into its infectious scrapie form (PrPSc).
The PrP fragment 106-126 (PrP106-126) has been reported
in numerous publications to elicit several e¡ects of prion path-
ology, i.e. to be toxic to cultured neurons [3^14] and to sup-
port the proliferation of glial cells [15] and microglia [16].
Cultures of cortical neurons derived from PrP0=0 mice, i.e.
devoid of cellular PrP, have been described to survive the
addition of PrP106-126 [4]. PrP106-126 is part of the NH2-
terminal £exible tail (residues 23^126) in the full-length mur-
ine PrP with a total of 231 residues [17]. The peptide polymer-
izes into ¢brils [9], assumes a L-sheet structure and forms
protease-resistant aggregates of high molecular mass [18].
Here, we describe experiments with neuronal cell cultures in
the presence of PrP106-126 under di¡erent conditions. The
experiments do not con¢rm the reported neurotoxicity of
the PrP fragment.
2. Materials and methods
2.1. Peptides
Two batches of PrP106-126 were purchased from Chiron Technol-
ogies (Clayton, Vic., Australia) with a purity higher than 95%. The
peptide sequence KTNMKHMAGAAAAGAVVGGLG was con-
¢rmed by mass spectroscopy, amino acid analysis and sequencing.
For aging, the peptide was incubated for at least 30 days at 37‡C in
0.1 M sodium phosphate, pH 7.4 [19]. Fibrils of PrP106-126 were
prepared by incubating the peptide at a concentration of 500 WM in
0.1 M sodium phosphate, pH 7.4, for 12 h at 25‡C. The peptide
solution was then subjected to ultracentrifugation at 540 000Ug for
3 h at 25‡C (Beckmann Optima TLX ultracentrifuge, TLA 100.3
¢xed-angle rotor). The resulting pellet was resuspended in H2O and
protein concentrations were determined with the BCA assay from
Pierce. PrP106-126 isoforms as they are produced during aging of
the peptide [19] were synthesized by replacing L-asparagine in the
third position (Asn-108 in PrP) with L-Asp, D-Asp, L-isoAsp or D-
isoAsp.
To test whether the reported neurotoxicity of peptide preparations
might be due to contaminants from their puri¢cation with high per-
formance liquid chromatography (HPLC), peptides were passaged
over a reverse-phase HPLC column. They eluted with a ¢nal concen-
tration of about 2 WM at approximately 30% acetonitrile/0.1% tri-
£uoroacetic acid (TFA). Peptide-containing fractions of 200 Wl each
were combined and concentrated 200-fold in a SpeedVac concentra-
tor. The sample was washed twice with water, corresponding to a
total dilution factor of eight. The peptide was then dried and resus-
pended in water to a concentration of 500 WM.
2.2. Animals
Mice (ICR, NMRI and C57Bl/6J) were either from BRL (Fu«llins-
dorf, Switzerland) or from their descendants bred at the Institute for
Laboratory Animal Science, University of Zu«rich. Rats (Wistar and
Zur:SD) were from the same two sources.
2.3. Cell cultures
Cortex and hippocampus were dissected as described [20] and cell
cultures were prepared according to the published protocols from the
laboratories of Forloni and Kretzschmar [3,4]. Cells were obtained at
embryonic (E) day 17 and in certain cases at day E16 or E18. The
tissue was treated for 5 min at 37‡C with 2.5 mg/ml trypsin (Life
Technologies) and 200 Wg/ml DNAse (Boehringer Mannheim), centri-
fuged, washed ¢ve times with 3 ml of serum-free Dulbecco’s minimal
essential medium (DMEM, Life Technologies) containing 5 mg albu-
max/ml (Life Technologies) and then mechanically dissociated in se-
rum-free medium containing 5 mg albumax/ml. Per well of a 96 well
microtiter plate, 40 000 cells in 40 Wl were placed corresponding to a
cell density of 5.2U105 cells/cm2. Either a solution of peptide in water
or water as a control was added to a ¢nal volume of 50 Wl. The
medium was exchanged (40 Wl) every second day. In 24 well plates,
cells were cultured in a total volume of 400 Wl at a cell density of
1.8U105 cells/cm2, corresponding to 320 000 cells per well, the me-
dium being exchanged (350 Wl) every second day. All wells were
coated with 50 Wg/ml poly-D-lysine (Sigma).
To suppress residual trypsin activity, 5 mg albumax/ml was added
throughout the culture period unless indicated otherwise. Cells were
incubated at 37‡C in a 5% CO2 atmosphere. Under serum-free con-
ditions, DMEM was supplemented with the de¢ned protein mix B27
(Life Technologies) [21,22], without adding cytosine-arabinoside (Ara-
C) or antibiotics. The ¢nal concentrations of ingredients of N2-sup-
plemented (Life Technologies) medium were: insulin (5 Wg/ml), human
transferrin (100 Wg/ml), progesterone (6.3 ng/ml), putrescine (16.11 Wg/
ml) and selenium (5.2 ng/ml). In certain experiments, 10% heat-inac-
0014-5793 / 99 / $20.00 ß 1999 Federation of European Biochemical Societies. All rights reserved.
PII: S 0 0 1 4 - 5 7 9 3 ( 9 9 ) 0 1 1 2 3 - 0
*Corresponding author. Fax: (41) (1) 635 6805.
E-mail: christen@biocfebs.unizh.ch
Abbreviations: Ara-C, cytosine-arabinoside; FCS, fetal calf serum;
MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide;
PrPSc, scrapie isoform of the prion protein; PrPc, cellular isoform
of the prion protein; TFA, tri£uoroacetic acid
FEBS 22567 1-9-99
FEBS 22567 FEBS Letters 458 (1999) 65^68
tivated fetal calf serum (FCS) was used instead of the de¢ned protein
mix B27. Serum batches from di¡erent companies were tested
(Amimed, Hyclone, Boehringer Mannheim, Biospa and Sigma).
Staining for living and dead cells was performed with the LIVE/
DEAD Viability/Cytotoxicity kit L-3224 according to the recommen-
dations of the supplier (Molecular Probes, Eugene, OR, USA). Fluo-
rescent cell stains were calcein AM for living cells and ethidium ho-
modimer-1 for dead cells. The preparation was examined with a
£uorescence microscope (Leitz DMR, Leica).
2.4. Assessing cell viability
3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)
assay [23,24]: a sterile-¢ltered stock solution of 5 mg MTT (cell cul-
ture grade, Sigma) per ml of phosphate-bu¡ered saline was added
directly to the wells to give a ¢nal concentration of 0.5 mg/ml. The
cells were incubated with MTT for 3 h at 37‡C. In the case of 24 well
plates, 300 Wl of the supernatant was subsequently carefully removed
and 300 Wl acidic isopropanol (0.04 N HCl in isopropanol) was added
to each well. In microtiter plates, 35 Wl was removed and 100 Wl acidic
isopropanol was added. The plates were then placed onto a lab shaker
continuously shaking at 200 rpm for 10 min to dissolve the formazan
crystals. Plates were read on a microtiter plate reader (Dynatech
MR7000) at 550 nm versus the reference wavelength of 750 nm. At
least every second day and just before starting the MTT assay, cells
were visually inspected with a Nikon microscope using phase contrast
optics.
3. Results and discussion
3.1. PrP106-126 does not impair cell viability
PrP106-126, when added to cultures of mouse cortical neu-
rons in di¡erent concentrations up to 200 WM, did not show
any toxic e¡ect (Fig. 1). This ¢nding is in contrast to previous
reports that described a cytotoxic e¡ect of the peptide at a
concentration of only 20 WM under comparable conditions
with hippocampal cultures from rats [3] and cortical cultures
from mice [4]. PrP106-126 proved to be non-neurotoxic also
towards hippocampal and cortical neurons from Wistar rats,
outbred NMRI mice and inbred mice C57BL/6J (Table 1).
Toxicity could depend on accompanying cells, e.g. astrocytes
or microglia which have been reported to support toxicity of
PrP106-126 [5] and to mediate a proliferative e¡ect of PrP106-
126 on astrocytes [16]. Microglial cells start to be found in the
brain around day E14 [25], whereas GFAP-positive glial cells
proliferate and di¡erentiate later [26]. To guarantee that non-
neuronal cell types were present, neurons were cultured from
di¡erent developmental stages, i.e. at days E16, E17 and E18.
None of these cultures was a¡ected by PrP106-126 (not
shown).
3.2. Variation of cell culture conditions
To exclude the possibility that an unknown toxic compo-
nent is attenuated by bovine serum albumin or particularly
e¡ective antioxidative components of the B27 medium supple-
ment used by us, control cultures were kept in the minimum
medium supplement N2. Since the neurotoxic e¡ect was orig-
inally shown in media containing 10% FCS [3], we tested
several batches of FCS (see Section 2). Again, all these con-
ditions were tested without ¢nding any evidence for PrP106-
126 being toxic (Table 1). Due to its higher protein content,
neurons generally show higher viability in B27-supplemented
than in N2-supplemented culture medium. Nevertheless, B27-
supplemented medium proved adequate to detect the neuro-
toxicity of the Alzheimer amyloid L-protein 1-42 [27], a ¢nd-
ing that was reproduced in our laboratory. PrP106-126 was
also found to be non-neurotoxic in low-density cultures using
mouse hippocampal neurons at a density of 100 000 cells per
ml (or per 8.5 cm2), followed by staining for living and dead
cells (not shown). In the studies reporting PrP106-126 to be
toxic, Ara-C was used to inhibit the proliferation of dividing
cells [3,4]. However, Ara-C also inhibits the proliferation of
microglial cells [28], calling into question the statement that
microglia support PrP106-126 toxicity [5]. We did not observe
any toxicity of the peptide in control cultures to which Ara-C
as well as the antibiotics penicillin and streptomycin were
added (not shown).
3.3. Neurotoxicity is not elicited by aggregation of PrP106-126
Conceivably, a prerequisite for neurotoxicity to become ap-
parent could be the formation of aggregates or ¢brils of
Table 1
Viability of cultured neuronal cells : synopsis of conditions tested
Experiment PrP106-126, 80 WM Species Strain Tissue Medium MTT ratio peptide/H2O þ S.D. n
1 Authentic Rat Wistar Hippocampus B27, albumax 0.98 þ 0.04 4
2 Authentic Rat Wistar Cortex B27, albumax 1.01 þ 0.03 4
3 Authentic Mouse C57BL/6J Cortex B27 1.09 þ 0.04 4
4 Authentic Mouse C57BL/6J Cortex B27, albumax 1.02 þ 0.04 4
5 Authentic Mouse NMRI Cortex FCS 0.96 þ 0.11 4
6 Authentic Mouse NMRI Cortex N2 0.99 1
7 Authentic Mouse NMRI Cortex B27 1.07 þ 0.18 2
8 Authentic Mouse NMRI Hippocampus B27, albumax 1.13 þ 0.07 3
9 Aged in media Mouse NMRI Hippocampus B27, albumax 1.07 þ 0.16 3
10 Authentic, HPLC Mouse NMRI Hippocampus B27, albumax 0.47 þ 0.05 2
11 Aged in phosphate, HPLC Mouse NMRI Hippocampus B27, albumax 0.50 þ 0.02 2
12 HPLC bu¡er Mouse NMRI Hippocampus B27, albumax 0.49 1
Bold print indicates the particular condition tested. PrP106-126 was used at 80 WM throughout these experiments. ‘Authentic’ stands for a stock
solution of the peptide freshly prepared in water, sterile-¢ltered and frozen for storage. ‘MTT ratio’ gives the absorption ratio of cultures con-
taining PrP106-126 to control cultures with H2O added. The absorption in a MTT assay corresponds to the number of viable cells. Experi-
ments 1 and 2 compare hippocampal with cortical neurons. Experiments 3 and 4 address the question if albumax as a medium supplement pre-
vents neurotoxicity of PrP106-126. Experiments 5^7 test for a di¡erence under the speci¢ed media conditions. (5) 10% FCS was used instead of
medium supplements. The MTT ratio corresponds to the average value from ¢ve di¡erent batches of serum. (6) The minimal medium supple-
ment N2 was used which has a lower antioxidative capacity than B27 used in (7). Experiments 8^12 serve to demonstrate that contaminants of
HPLC bu¡er such as acetonitrile or TFA might be toxic. Experiments 8 and 9 are the controls for experiments 10^12: (8) authentic peptide,
(9) PrP106-126 aged in cell culture medium without supplement for 2 weeks at 37‡C, (10) PrP106-126 eluted from a reverse-phase HPLC col-
umn with acetonitrile/TFA, (11) aged PrP106-126 after HPLC with acetonitrile/TFA, (12) HPLC bu¡er, i.e. 30% acetonitrile/0.1% TFA after
concentration by SpeedVac. For details of the experiments, see Section 2.
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PrP106-126. New stock solutions of PrP106-126 were rou-
tinely ¢ltered to maintain them sterile and endotoxin-free
for direct use in cell cultures without antibiotics. Removal
of ‘seeds’ by ¢ltering the peptide preparation through a 0.2
Wm membrane might abolish toxicity. A sterile-¢ltered sample
of PrP106-126 was tested together with non-¢ltered material,
a preparation of ¢brils of PrP106-126 (see Section 2) and a
control without peptide. Visual inspection by phase contrast
microscopy did not reveal any toxic e¡ects under any condi-
tion. The results were veri¢ed by MTT viability tests with cell
cultures after 8 days (Fig. 1). No signi¢cant di¡erence in cell
viability between control and addition of sterile-¢ltered
PrP106-126, non-¢ltered or ¢brillar peptide was observed.
Floating, translucent material thought to represent peptide
aggregates was observed 1 day after the peptide was added
in all wells of 24 well plates containing 80 WM PrP106-126.
3.4. None of the isoforms of PrP106-126 exerts a toxic e¡ect
on neurons
Asn-108 of PrP106-126 becomes spontaneously deamidated
to aspartic acid and isoaspartic acid with a half-time of 12
days [19]. Consequently, an aged solution of the peptide is to
be expected to be contaminated with these isoforms, which
might be responsible for the putative neuronal toxicity ob-
served in other laboratories. The situation could be the
same as for Alzheimer amyloid L-peptide 1-42, the toxicity
of which has been shown to depend on aged peptide material
[29] and the content of L-sheet structure which is adopted by
incubation in water for several days [30]. For PrP106-126, a
report claiming an increased e⁄cacy upon aging in inducing
cation permeability of arti¢cial bilayer membranes suggested a
similar process [31].
Aged PrP106-126 (see Section 2), peptide aged in culture
medium for 14 days, the corresponding separate isoforms
of PrP106-126 (containing L-Asp, L-isoAsp, D-Asp, D-isoAsp
instead of Asn-108) and an equimolar mixture of the iso-
forms (20 WM each) were tested for toxicity. We found no
toxic e¡ect of all these peptides (for the results with aged
PrP106-126, see Table 1; the data with the isoforms are not
shown).
3.5. Components of HPLC bu¡er are toxic to neurons
In our hands, the only conditions where we found neuronal
toxicity of a preparation of PrP106-126 was after its passage
over an HPLC column under certain conditions. When the
peptide was subjected to reverse-phase chromatography at a
low concentration (2 WM) and was concentrated to a ¢nal
concentration of 500 WM (see Section 2), the peptide prepara-
tion became toxic. The toxic e¡ect was comparable to that of
HPLC bu¡er in fractions from runs without peptide subjected
to the same concentration procedure (Table 1). In summary,
the toxic e¡ect of PrP106-126 preparations seems to be due to
an unidenti¢ed contaminant, e.g. of microbial origin or result-
ing from the synthesis or the HPLC puri¢cation, rather than
due to the peptide itself.
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